Sean Moran Sells 12,000 Shares of Corbus Pharmaceuticals (NASDAQ:CRBP) Stock

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) CFO Sean Moran sold 12,000 shares of Corbus Pharmaceuticals stock in a transaction that occurred on Friday, August 7th. The shares were sold at an average price of $10.08, for a total transaction of $120,960.00. Following the sale, the chief financial officer owned 84,694 shares of the company’s stock, valued at approximately $853,715.52. The trade was a 12.41% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Corbus Pharmaceuticals Price Performance

CRBP stock opened at $9.51 on Wednesday. The company has a market capitalization of $177.55 million, a P/E ratio of -1.54 and a beta of 2.59. Corbus Pharmaceuticals Holdings, Inc. has a 12 month low of $7.12 and a 12 month high of $20.56. The firm’s fifty day simple moving average is $8.79 and its 200-day simple moving average is $9.06.

Corbus Pharmaceuticals (NASDAQ:CRBP) last issued its earnings results on Thursday, August 6th. The biopharmaceutical company reported ($1.81) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.26) by ($0.55). As a group, sell-side analysts forecast that Corbus Pharmaceuticals Holdings, Inc. will post -5.22 earnings per share for the current year.

Hedge Funds Weigh In On Corbus Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of the business. Bank of New York Mellon Corp acquired a new position in Corbus Pharmaceuticals in the 2nd quarter worth about $425,000. Seven Fleet Capital Management LP raised its stake in shares of Corbus Pharmaceuticals by 51.0% during the 1st quarter. Seven Fleet Capital Management LP now owns 85,687 shares of the biopharmaceutical company’s stock worth $805,000 after buying an additional 28,937 shares during the period. Bank of America Corp DE raised its stake in shares of Corbus Pharmaceuticals by 53,592.3% during the 1st quarter. Bank of America Corp DE now owns 13,960 shares of the biopharmaceutical company’s stock worth $131,000 after buying an additional 13,934 shares during the period. Royal Bank of Canada lifted its position in shares of Corbus Pharmaceuticals by 81.2% during the 1st quarter. Royal Bank of Canada now owns 29,901 shares of the biopharmaceutical company’s stock valued at $281,000 after buying an additional 13,401 shares in the last quarter. Finally, Exome Asset Management LLC grew its stake in Corbus Pharmaceuticals by 67.8% in the 1st quarter. Exome Asset Management LLC now owns 234,136 shares of the biopharmaceutical company’s stock valued at $2,199,000 after acquiring an additional 94,593 shares during the period. Hedge funds and other institutional investors own 64.64% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have recently commented on CRBP. Weiss Ratings restated a “sell (d-)” rating on shares of Corbus Pharmaceuticals in a research note on Friday, July 17th. Mizuho decreased their price target on Corbus Pharmaceuticals from $44.00 to $34.00 and set an “outperform” rating for the company in a report on Tuesday, June 23rd. Guggenheim restated a “buy” rating on shares of Corbus Pharmaceuticals in a research report on Tuesday, May 26th. Wedbush dropped their price objective on shares of Corbus Pharmaceuticals from $38.00 to $30.00 and set an “outperform” rating on the stock in a research note on Wednesday, May 27th. Finally, HC Wainwright cut their target price on shares of Corbus Pharmaceuticals from $40.00 to $35.00 and set a “buy” rating for the company in a report on Friday, August 7th. Eight analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $41.12.

More Corbus Pharmaceuticals News

Here are the key news stories impacting Corbus Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright maintained a Buy rating and a $35 price target, while the broader analyst consensus remains “Moderate Buy” with an average target of $41.12. The firm also projects a return to profitability by 2030, despite near-term losses. HC Wainwright Cuts Corbus Pharmaceuticals Price Target
• Positive Sentiment: Several institutional investors increased their positions, including OrbiMed Advisors, Armistice Capital, Prosight Management, ADAR1 Capital Management, and Renaissance Technologies. Institutional ownership stands at approximately 64.6%, which may offer some support for the shares.
• Neutral Sentiment: The reported short-interest data shows zero shares sold short and a zero-day short-interest ratio. Because both the current and prior short-interest figures are listed as zero, the reported percentage increase is not meaningful and does not indicate notable short-covering or bearish positioning.
• Negative Sentiment: HC Wainwright reduced EPS forecasts across 2026–2030: 2026 is now expected at a $6.11 loss per share versus a prior $4.99 loss, while 2027–2029 loss estimates also widened materially. Its 2030 forecast fell to $0.15 from $1.29, signaling a slower path to profitability. Analysts Offer Insights on Corbus Pharmaceuticals
• Negative Sentiment: Oppenheimer lowered its price target to $48 from $52, and HC Wainwright cut its target to $35 from $40, although both firms remain positive on CRBP. Oppenheimer Cuts Corbus Pharmaceuticals Price Target
• Negative Sentiment: CEO Yuval Cohen sold 17,000 shares and CFO Sean Moran sold 12,000 shares at $10.08 per share, reducing their direct holdings by roughly 9.8% and 12.4%, respectively. The company also recently reported a quarterly loss of $1.81 per share, worse than the $1.26 analyst consensus.

About Corbus Pharmaceuticals

Corbus Pharmaceuticals Holdings, Inc is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of therapeutic candidates for rare, life-threatening inflammatory and fibrotic diseases. The company’s lead investigational therapy, lenabasum, is a synthetic, oral cannabinoid receptor type 2 (CB2) agonist designed to resolve chronic inflammation by harnessing the body’s innate resolution pathways. Corbus operates by advancing small-molecule compounds through preclinical and clinical studies to address unmet medical needs in autoimmune and inflammatory disorders.

Lenabasum is currently under evaluation in a Phase 3 clinical trial for diffuse cutaneous systemic sclerosis (dcSSc) and in a Phase 2 study for cystic fibrosis–related inflammation.